Thymulin
Thymulin (Zn-FTS, facteur thymique sérique) is a zinc-dependent nonapeptide secreted by thymic epithelial cells that plays a critical role in T-cell maturation, immune regulation, and thymic function. It requires zinc for biological activity and declines with age in parallel with thymic involution.
Thymulin (also known as Zn-FTS or facteur thymique sérique) is a naturally occurring zinc-dependent nonapeptide hormone secreted exclusively by thymic epithelial cells. Discovered by Jean-François Bach and colleagues in the early 1970s, thymulin is the only thymic hormone that requires a metal cofactor (zinc) for biological activity.
Overview
Thymulin was first identified as "facteur thymique sérique" (FTS, serum thymic factor) by Bach & Dardenne (1973) using a rosette inhibition assay that detected a serum factor capable of inducing T-cell differentiation markers. In 1977, the nonapeptide structure was elucidated, and the absolute requirement for zinc was established by Dardenne et al. (1982), leading to the designation Zn-FTS and later the name thymulin.
Thymulin is the only thymic peptide produced exclusively by the thymus. Unlike thymosin alpha-1 and thymosin beta-4, which are expressed in multiple tissues, thymulin production ceases entirely after thymectomy, confirming its thymus-specific origin. Serum thymulin levels peak in early childhood, begin declining in adolescence, and are often undetectable by age 60 — a timeline that mirrors the progressive fatty replacement of functional thymic tissue known as thymic involution.
The zinc requirement gives thymulin a distinctive dual role: it functions both as a thymic hormone driving T-cell maturation and as a biological indicator of systemic zinc status. Zinc deficiency, whether from malnutrition, aging, or disease, renders circulating thymulin biologically inactive even when peptide levels are adequate.
Mechanism of Action
T-Cell Maturation: Thymulin promotes the differentiation of immature thymocytes into mature T lymphocytes within the thymus. It induces expression of T-cell surface markers including CD2, CD3, CD4, and CD8, and enhances T-cell receptor gene rearrangement. Dardenne et al. (1982) demonstrated that thymulin drives the transition from CD4⁻CD8⁻ double-negative precursors to mature single-positive T cells.
Immune Regulation: Thymulin modulates cytokine production by mature T cells and macrophages. It enhances IL-2 production and IL-2 receptor expression while suppressing excessive pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6) in inflammatory contexts. This bidirectional activity contributes to immune homeostasis rather than simple immunostimulation.
NK Cell Enhancement: Thymulin increases natural killer cell cytotoxicity and interferon-gamma production. Mocchegiani et al. (1995) showed that zinc-sufficient thymulin enhances NK cell-mediated tumor lysis in aging models.
Zinc-Dependent Activation: The zinc-binding event is the critical activation step. In the absence of zinc, the FTS peptide exists in solution but cannot bind its receptor or exert immunomodulatory effects. This makes thymulin activity a direct readout of zinc bioavailability. Prasad et al. (1988) demonstrated that dietary zinc supplementation restores thymulin activity in zinc-deficient elderly subjects.
Anti-inflammatory Signaling (CNS): In central nervous system models, thymulin and its analogs suppress NF-κB signaling and reduce microglial activation, providing neuroprotective effects against neuroinflammation. Lunin & Bhatt (2015) showed that intranasal thymulin analogs reduce neuroinflammatory markers in demyelination models.
Research
T-Cell Maturation and Thymic Function
Thymulin's primary physiological role is driving intrathymic T-cell differentiation. Bach (1983) established that thymulin is essential for the terminal stages of T-cell maturation within the thymus, particularly the transition from cortical to medullary thymocytes. Thymectomy eliminates circulating thymulin and impairs new T-cell production, effects that can be partially reversed by thymulin administration.
Savino et al. (1984) demonstrated that thymulin is produced specifically by thymic epithelial cells of the subcapsular cortex and medulla, and that its secretion is regulated by a neuroendocrine feedback loop involving the pituitary gland, growth hormone, and prolactin.
Zinc Deficiency and Immune Function
The zinc-thymulin axis has been extensively studied in human zinc deficiency. Prasad et al. (1988) conducted landmark studies showing that even mild zinc deficiency causes profound loss of thymulin activity, leading to impaired T-cell function, decreased NK cell activity, and increased susceptibility to infections. Zinc supplementation restored thymulin activity and immune function in elderly subjects.
Mocchegiani et al. (1995) extended these findings in aging populations, showing that age-related decline in thymulin activity is at least partially attributable to declining zinc status rather than thymic involution alone. Zinc supplementation in elderly individuals restored serum thymulin to levels comparable to younger adults.
Aging and Immunosenescence
Thymulin is one of the most reliable biomarkers of thymic aging. Fabris et al. (1988) tracked serum thymulin across the human lifespan, demonstrating peak levels at ages 2-10, progressive decline through adolescence and adulthood, and negligible levels by age 60. This decline precedes and may contribute to the broader immunosenescence phenotype.
Goya et al. (2007) used adenoviral-mediated thymulin gene therapy in aging rats, restoring thymulin levels and partially reversing age-related immune decline. Treated animals showed improved T-cell proliferative responses and enhanced vaccine responses.
Intranasal Delivery for Neuroinflammation
A newer line of research explores thymulin and its analogs as anti-neuroinflammatory agents delivered intranasally to bypass the blood-brain barrier. Lunin et al. (2013) demonstrated that intranasal thymulin reduces brain inflammation in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, by suppressing pro-inflammatory cytokine production in the CNS.
Safieh-Garabedian et al. (2011) showed that thymulin analogs with enhanced stability reduce neuroinflammation and pain in rat models of peripheral nerve injury, suggesting potential applications in neuropathic pain and neuroinflammatory conditions.
Autoimmune Disease
Paradoxically, thymulin levels are altered in several autoimmune conditions. Bach & Dardenne (1989) reported that thymulin activity is elevated in early-stage type 1 diabetes and systemic lupus erythematosus, potentially reflecting compensatory thymic hyperactivity, before declining in advanced disease as the thymus becomes exhausted.
Safety Profile
Thymulin has a favorable safety profile based on animal studies and limited human research:
- Injection site reactions: Minimal; thymulin is well tolerated subcutaneously
- Systemic effects: No significant adverse events reported in clinical or preclinical studies
- Zinc dependency: Activity requires adequate zinc status; zinc supplementation may be necessary in deficient individuals
- Short half-life: Rapid clearance (~15-30 minutes) limits duration of effect but also reduces risk of sustained adverse effects
- Intranasal: Well tolerated in preclinical intranasal delivery studies; no mucosal irritation reported
- Contraindications: Theoretical concern in active autoimmune disease (thymulin may modulate autoimmune processes); use with caution in conditions of zinc overload
Pharmacokinetic Profile
Thymulin — Pharmacokinetic Curve
Subcutaneous, intranasal (research)Quick Start
- Typical Dose
- 1-10mcg per injection (research protocols)
- Frequency
- Daily during research protocols
- Route
- Subcutaneous, intranasal (research)
- Cycle Length
- Varies by research protocol
- Storage
- Reconstituted: 2-8°C, use within 4 weeks
Molecular Structure
- Formula
- C₃₃H₅₄N₁₀O₁₅Zn (zinc-bound)
- Weight
- 857 Da
- Length
- 9 amino acids
- CAS
- 63958-90-7
- PubChem CID
- 71300623
- Exact Mass
- 858.3832 Da
- LogP
- -10.9
- TPSA
- 452 Ų
- H-Bond Donors
- 15
- H-Bond Acceptors
- 16
- Rotatable Bonds
- 28
- Complexity
- 1610
Identifiers (SMILES, InChI)
InChI=1S/C33H54N12O15/c1-15(39-29(55)18-6-8-24(50)40-18)27(53)42-16(4-2-3-9-34)30(56)45-21(14-47)32(58)43-17(5-7-22(35)48)28(54)38-11-25(51)37-12-26(52)41-20(13-46)31(57)44-19(33(59)60)10-23(36)49/h15-21,46-47H,2-14,34H2,1H3,(H2,35,48)(H2,36,49)(H,37,51)(H,38,54)(H,39,55)(H,40,50)(H,41,52)(H,42,53)(H,43,58)(H,44,57)(H,45,56)(H,59,60)/t15-,16-,17-,18-,19-,20-,21?/m0/s1
LIFNDDBLJFPEAN-YTAPOSPOSA-NResearch Indications
Immune System Research
Age-related decline in thymulin correlates with reduced immune function; supplementation may restore T-cell parameters.
Promotes differentiation and maturation of T-lymphocytes in thymus.
Thymulin activity depends on zinc; studied in zinc-depleted conditions.
Inflammatory & Autoimmune Research
Research shows thymulin suppresses pro-inflammatory cytokines and mediators.
Investigated for potential to restore immune balance in autoimmune states.
Studied for effects on pancreatic beta cells and immune modulation in diabetes models.
Neuroendocrine Research
Thymulin influences hypothalamic-pituitary-adrenal axis function.
Some research suggests protective effects on neural tissue.
Research Protocols
subcutaneous Injection
Thymulin is typically administered via subcutaneous or intraperitoneal injection in research settings. As a small peptide, it can also be explored via intranasal delivery for CNS effects. Zinc status should be adequate for biological activity.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Research protocol (immune) | 1-10 mcg | Daily | —(Route: SubQ) |
| Intranasal (experimental) | Variable | As studied | —(Route: Intranasal) |
Reconstitution Guide (mg vial + mL BAC water)
- Ensure adequate zinc supplementation for activity
- Reconstitute with bacteriostatic water
- Inject water slowly down vial wall
- Gently swirl until dissolved
- Store refrigerated at 2-8°C
- Use within 4 weeks of reconstitution
Interactions
Peptide Interactions
Different thymic peptides with complementary mechanisms.
Thymalin is a peptide mixture while thymulin is a single defined peptide; can complement each other.
Different mechanisms; no known negative interactions.
Different mechanisms; no known interactions.
What to Expect
What to Expect
Receptor binding and initial cellular signaling
Immune cell modulation begins; cytokine profile changes
T-cell differentiation effects; measurable immune parameters
Long-term immune restoration in research models
Safety Profile
Common Side Effects
- Generally well-tolerated in research
- Injection site reactions (mild)
Contraindications
- Autoimmune diseases (use with medical supervision)
- Organ transplant recipients on immunosuppression
- Pregnancy or breastfeeding
- Known hypersensitivity to thymic peptides
Discontinue If
- Signs of allergic reaction
- Unexpected immune changes
Quality Indicators
What to look for
- White lyophilized powder
- Clear solution after reconstitution
- Intact vacuum seal
- Certificate of analysis with sequence verification
Caution
- Slight clumping that dissolves easily
Red flags
- Discolored powder
- Cloudy solution after reconstitution
- Particulates present
- Broken seal
Frequently Asked Questions
References (17)
- [9]
- [8]
- [1]Thymulin (FTS) - A Thymic Hormone (1989)
- [2]The neuroendocrine role of thymulin (2000)
- [3]Zinc and thymulin
- [4]Thymulin and aging
- [15]
- [16]Martínez-Lazcano et al — Anti-inflammatory and neuroprotective effects of thymulin on trimethyltin-induced neurotoxicity (2022)
- [17]
- [5]Bach JF, Dardenne M Studies on thymus products. II. Demonstration and characterization of a circulating thymic hormone Immunology (1973)
- [7]
- [6]Dardenne M, Pléau JM, Nabarra B, et al Contribution of zinc and other metals to the biological activity of the serum thymic factor Proc Natl Acad Sci USA (1982)
- [11]Mocchegiani E, Muzzioli M, Giacconi R, et al Metallothioneins/PARP-1/IL-6 interplay on natural killer cell activity in elderly: parallelism with nonagenarians and old infected humans. Effect of zinc supply Mech Ageing Dev (1995)
- [10]Fabris N, Mocchegiani E, Amadio L, et al Thymic hormone deficiency does not depend on the lack of Zn supply in old mice Mech Ageing Dev (1988)
- [12]Goya RG, Reggiani PC, Vesenbeckh SM, et al Thymulin gene therapy prevents the reduction of thymulin serum levels and restores immune function in old animals Biomed Pharmacother (2007)
- [14]Safieh-Garabedian B, Kanaan SA, Haddad JJ, et al Thymulin reduces hyperalgesia and cytokine upregulation in a rat model of neuropathic pain Brain Behav Immun (2011)
- [13]Lunin SM, Glushkova OV, Khrenov MO, et al Thymulin, a thymic peptide, prevents the overproduction of pro-inflammatory cytokines and heat shock protein Hsp70 in inflammation Immunol Invest (2013)
Thymosin Beta-10
Thymosin beta-10 (Tβ10) is a 43-amino acid actin-binding peptide closely related to thymosin beta-4 (TB-500) that regulates actin dynamics, cell motility, and apoptosis. Unlike its pro-angiogenic sibling TB4, Tβ10 demonstrates anti-angiogenic and potential anti-tumorigenic properties, making it a subject of cancer biology research.
Tirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).